A study identifies critical thresholds for future liver remnant volume (FLRV) to reduce post-hepatectomy liver failure in cancer patients.

• FLRV of ≥30% in normal livers and ≥50% in impaired livers reduces the risk of severe morbidity.
• For every 10% increase in FLRV, the odds of severe liver failure-related complications decrease by nearly 40%.

Focus on maintaining these thresholds in surgical planning to improve patient outcomes.

• 51% overall morbidity was noted, with 3.2% experiencing grade 4/5 complications; half of these were unrelated to liver failure.

In-hospital mortality after pancreatoduodenectomy reveals critical timing for interventions impacting patient outcomes.

• 3.5% of patients (156 of 4474) died in the hospital, primarily from three complication clusters: postpancreatectomy-specific (51.9%), vascular (25.6%), and cardiopulmonary (17.9%).
• Complications emerge at different postoperative intervals: median 9 days for postpancreatectomy, 4.5 days for vascular, and 3 days for cardiopulmonary issues.

Timing matters—intervene sooner for vascular and cardiopulmonary issues to improve survival rates.

• After postpancreatectomy complications, the median time to death was 31 days; for vascular issues, it was 18 days, and for cardiopulmonary, just 1 day.

Routine CA 19-9 surveillance detects recurrences early and enhances survival in resected ampullary cancer patients.

• Five-year overall survival stands at 56.4% in 572 patients, with 43.88% experiencing recurrences, predominantly distant.
• A serial rise in CA 19-9 is a strong predictor for recurrence, showing 71.05% sensitivity and 91.67% specificity.

Detecting recurrences early through CA 19-9 testing results in a median survival of 12.8 months versus 7.6 months without the elevated marker.

• Absolute CA 19-9 levels over 200 U/ml correlated with recurrence in nearly 93% of cases.